Kaplan-Meier plots of PFS (a) and OS (b) according to postsurgical UICC stages.

<p>Kaplan-Meier plots of PFS (a) and OS (b) according to postsurgical UICC stages.</p

Kaplan-Meier plots of progression-free survival (a) and overall survival (b).

<p>Kaplan-Meier plots of progression-free survival (a) and overall survival (b).</p

Chemotherapy related adverse effects during preoperative and postoperative treatment phase.

<p>Chemotherapy related adverse effects during preoperative and postoperative treatment phase.</p

Outcome.

<p>Outcome.</p

Baseline patient characteristics.

<p>Baseline patient characteristics.</p

Kaplan-Meier estimates of recurrence free survival (RFS) and overall survival (OS).

<p>(A) OS in the entire cohort (n = 104) at 2 years was 87.3% (95% CI, 80.5–94.1%) and 75.6% (95% CI, 65.2–86.0%) at 5 years; ◆ indicates calculated survival probability according to MSKCC nomogram at 4, 8, and 12 years. (B) RFS in the entire cohort at 2 and 5 years was 68.1% (95% CI, 58.5–77.7%) and 61.2% (95% CI, 50.4–71.6%) (C) OS stratified by tumor localization (extremities only cohort 90.5% (95% CI, 83.7–97.3%) and 79.0% (95% CI, 68.4–89.6%) at 2 and 5 years. (D) RFS stratified by tumor localization (extremities only cohort was 74.0% (95% CI, 64.0–84.0%) and 65.3% (95% CI, 53.7–76.9%) at 2 and 5 years.</p

Treatment related toxicities according to CTC.

<p>Treatment related toxicities according to CTC.</p

Treatment protocol and adherence to protocol.

<p>Treatment protocol and adherence to protocol.</p

Risk of relapse.

<p>(A) Cumulative risk of locoregional relapse: 5.7% (95% CI, 0.7–10.7%) at 2 years and 11.3% (95% CI, 3.5–19.1%) at 5 years. (B) Cumulative risk of distant relapse: 25.9% (95% CI, 16.7–35.1%) at 2 years and 29.2% (95% CI, 19.4–39.0%) at 5 years.</p